Context Therapeutics Inc. (CNTX)
Chart Events
Performance Outlook
| Previous Close | 0.6099 |
| Open | 0.5992 |
| Bid | 0.6107 x 1300 |
| Ask | 0.6200 x 1100 |
| Day's Range | 0.5801 - 0.6273 |
| 52 Week Range | 0.5600 - 2.7900 |
| Volume | |
| Avg. Volume | 2,067,391 |
| Market Cap | 9.899M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.1070 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
Company prioritizing pipeline to focus on CTIM-76 development and discontinuing ONA-XR program Cash runway extended into late 2024 CTIM-76 preclinical data to be presented at AACR Annual Meeting 2023 PHILADELPHIA, March 22, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced financial results for the year ended December 31, 2022. Additionally, the Company announce
- GlobeNewswire
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ETPHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company developing novel treatments for solid tumors, with a primary focus on female cancers, today announced that an abstract regarding Context’s preclinical candidate, CTIM-76, a Claudin 6 x CD3 bispecific antibody, has been selected for poster presentation
- GlobeNewswire
UPDATE -- Diamond Equity Research Initiates Coverage on Context Therapeutics Inc. (NASDAQ: CNTX)
NEW YORK, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Context Therapeutics Inc. (NASDAQ: CNTX). The in-depth 26-page initiation report includes detailed information on the Context Therapeutics’ business model, services, industry, valuation, management, and risks. The full research report is available here. Highlights from the report include: Promising Pipeline of Novel Sy
